2025-12-12 - LD Munich - Zentiva v. Sanofi - UPC_CFI_503/2024
- Aktenzeichen:
- UPC_CFI_503/2024
- Datum:
- Spruchkörper:
- Court of First Instance - Munich (DE) Local Division
- Art:
- Order
- Parteien:
- Sanofi SA as successor of Sanofi Mature IP a.o. v. Zentiva France a.o.
Kernaussage: Munich LD revoked Sanofi cabazitaxel patent (EP 2 493 466) in entirety — lack of inventive step based on Phase III TROPIC clinical trial data.
2025-12-12 - LD Munich - Zentiva
v.
Sanofi - UPC_CFI_503/2024
landmark
Munich LD revoked Sanofi cabazitaxel patent (EP 2 493 466) in entirety — lack of inventive step based on Phase III TROPIC clinical trial data. Three consolidated infringement actions against generics (STADA, Dr Reddy's, Zentiva) dismissed. Reasonable expectation of success, not mere hope. Consistent with TJ Paris; EPO BoA not followed.
Nichtigkeitsgründe
Art. 138 EPCInventive Step
Patent invalid (this ground)Art. 56 EPC · Art. 138(1)(a) EPC
“Revoked — reasonable expectation of success from Phase III TROPIC trial.”